Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label galcanezumab safety study in episodic or chronic cluster headache
NL-OMON47489Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of galcanezumab in Cluster Headache (CH), sponsored by Eli Lilly and Company. Primary endpoints: Treatment-emergent adverse events, Serious adverse events and 1 more. Started Sep 2017; status: active, not recruiting.
02
Drugs
galcanezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NL-OMON47489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47489.